Provided by Tiger Trade Technology Pte. Ltd.

ResMed

233.61
-0.9900-0.42%
Volume:100.74K
Turnover:23.60M
Market Cap:32.94B
PE:22.40
High:236.86
Open:236.26
Low:233.16
Close:234.60
52wk High:277.67
52wk Low:180.27
Shares:141.00M
Float Shares:140.00M
Volume Ratio:0.59
T/O Rate:0.07%
Dividend:2.40
Dividend Rate:1.03%
EPS(TTM):10.43
EPS(LYR):10.43
ROE:24.27%
ROA:14.00%
PB:5.00
PE(LYR):22.40

Loading ...

Analysts Offer Insights on Healthcare Companies: RegenXBio (RGNX) and Resmed (RMD)

TIPRANKS
·
Sep 25

ResMed Inc. Stock Falls Friday, Underperforms Market

Dow Jones
·
Sep 19

Sleep Device Maker ResMed Gets an Upgrade. Analysts See a Lot to Like.

Dow Jones
·
Sep 16

Movement Alert|ResMed Rises 5.09% in Regular Trading, RBC Upgrades to Outperform With Higher Price Target

Market Focus
·
Sep 16

S&P 500 Top and Bottom Performing Stocks at About 12:00 P.m. EDT

Reuters
·
Sep 16

Resmed Inc Stock (RMD) Moved Up by 3.05% on Sep 15: A Full Analysis

TradingKey
·
Sep 15

ResMed Projected to Attain High-Single-Digit EPS Growth in Next Three Years, RBC Says

MT Newswires Live
·
Sep 15

RBC Upgrades ResMed to Outperform From Sector Perform, Raises Price Target to $262 From $244

MT Newswires Live
·
Sep 15

Resmed Inc. : RBC Raises to Outperform from Sector Perform; Raises Target Price to $262 from $244

THOMSON REUTERS
·
Sep 15

U.S. Research Roundup-Eli Lilly, McDonald's, Welltower

Reuters
·
Sep 15

ResMed Inc. Stock Rises Monday, Outperforms Market

Dow Jones
·
Sep 15

'I'm the Executor': My Two Siblings and I Inherited an IRA. Can We Just Cash it Out?

Dow Jones
·
Sep 12

'I'm the Executor': My Two Siblings and I Inherited an IRA. Can We Just Cash it Out?

Dow Jones
·
Sep 11

ResMed CEO Michael Farrell Exercises Options and Sells Shares Under 10b5-1 Plan

TIPRANKS
·
Sep 11

Resmed Inc.-Statement of Changes in Beneficial Ownership

THOMSON REUTERS
·
Sep 11

Statement of Changes in Beneficial Ownership-RMD.N

Reuters
·
Sep 11

ResMed CEO Michael J. Farrell Disposes of Common Shares Worth $1,110,188.53

Reuters
·
Sep 10

ResMed price target raised to $240 from $235 at Citi

TIPRANKS
·
Sep 10

Citigroup Adjusts Price Target on ResMed to $240 From $235, Keeps Neutral Rating

MT Newswires Live
·
Sep 10

'I'm the Executor': My Two Siblings and I Inherited an IRA. Can We Just Cash it Out?

Dow Jones
·
Sep 10